{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-008339","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2024-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.022716+00:00","generated_at":"2026-06-05T04:46:24.838221+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"C4 Therapeutics enters collaboration with Merck KGaA for two protein degraders; $16M upfront, up to $740M milestones","bullets":["Upfront payment of $16 million from Merck KGaA; Merck to fund discovery research costs.","C4T eligible for up to approximately $740 million in discovery, regulatory, and commercial milestone payments.","Tiered royalties on net sales: mid-single to low-double digit percent.","Collaboration on two targeted protein degraders from C4T's internal oncology pipeline.","Merck KGaA responsible for clinical development and commercialization; C4T uses TORPEDO platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-008339","json":"https://secwatch.observer/filing/0001628280-24-008339.json","markdown":"https://secwatch.observer/filing/0001628280-24-008339.md","text":"https://secwatch.observer/filing/0001628280-24-008339.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024008339/0001628280-24-008339-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024008339/cccc-20240304.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:46:24.838221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ea61dab7a85a29cad269a9ec64a6ef305fb087a","claim":"C4 Therapeutics, Inc. entered into Research Collaboration and License Agreement with Merck KGaA, Darmstadt, Germany (operating as EMD Serono in U.S. and Canada) valued at upfront cash payment of $16.0 million; aggregate potential milestone payments of approximately $740 (effective 2024-03-01).","evidence_excerpt":"On March 1, 2024 , C4 Therapeutics, Inc. (“ C4T ”) entered into a Research Collaboration and License Agreement (“ License Agreement ”) with Merck KGaA, Darmstadt, Germany (“ MKDG ”), which operates its healthcare business as EMD Serono in the U.S. and Canada, to exclusively discover two targeted protein degraders against critical oncogenic proteins that C4T has progressed within its internal discovery pipeline.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024008339/0001628280-24-008339-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Merck KGaA, Darmstadt, Germany (operating as EMD Serono in U.S. and Canada)"},{"label":"Value","value":"upfront cash payment of $16.0 million; aggregate potential milestone payments of approximately $740"},{"label":"Effective","value":"2024-03-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}